Adlai Nortye Ltd. American Depositary Shares - Asset Resilience Ratio
Adlai Nortye Ltd. American Depositary Shares (ANL) has an Asset Resilience Ratio of 0.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Adlai Nortye Ltd. American Depositary Sh debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Adlai Nortye Ltd. American Depositary Shares's Asset Resilience Ratio has changed over time. See ANL net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Adlai Nortye Ltd. American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adlai Nortye Ltd. American Depositary Sh (ANL) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.00K | 0.01% |
| Total Liquid Assets | $7.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Adlai Nortye Ltd. American Depositary Shares maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Adlai Nortye Ltd. American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare Adlai Nortye Ltd. American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Adlai Nortye Ltd. American Depositary Shares (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Adlai Nortye Ltd. American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.01% | $7.00K | $71.27 Million | -5.37pp |
| 2023-12-31 | 5.38% | $7.01 Million | $130.19 Million | -23.94pp |
| 2022-12-31 | 29.32% | $21.29 Million | $72.59 Million | -11.54pp |
| 2021-12-31 | 40.86% | $53.81 Million | $131.69 Million | +40.21pp |
| 2020-12-31 | 0.66% | $241.00K | $36.74 Million | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more